As previously reported, Barclays downgraded Sanofi (SNY) to Equal Weight from Overweight with an EUR 85 price target as the firm transferred coverage of European large-cap pharma to a new analyst. The downgrade balances a low valuation and “strong” operational outlook with the lack of late stage pipeline opportunities and the approaching Dupixent loss of exclusivity, the analyst tells investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi downgraded to Equal Weight from Overweight at Barclays
- Kennedy scales back number of vaccines recommended for children, NYT says
- Sanofi and Regeneron Expand Dupilumab’s Real-World Footprint in Chronic Urticaria
- Trump Weekly: Furniture tariffs delayed, drugmakers hike prices
- Midday Fly By: Nvidia said to see strong H200 demand in China